Lv57
958 积分 2025-11-19 加入
Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, provides robust HbA1c and body weight reductions to people with type 2 diabetes: a 36--week, phase 2 study
8天前
已关闭
CD146, a therapeutic target involved in cell plasticity
2个月前
已完结
Isolation and characterization of human umbilical cord-derived mesenchymal stem cells from preterm and term infant
2个月前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
4个月前
已完结
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
4个月前
已完结
皖公网安备34019202002308
